Benitec Biopharma Limited (BLT.AX)
-ASX 0.02 
0.00(6.67%) 9:59PM EDT
| Prev Close: | 0.02 |
|---|
| Open: | 0.02 |
|---|
| Bid: | 0.02 |
|---|
| Ask: | 0.02 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.02 - 0.02 |
|---|
| 52wk Range: | 0.01 - 0.02 |
|---|
| Volume: | 1,120,000 |
|---|
| Avg Vol (3m): | 1,725,620 |
|---|
| Market Cap: | 16.79M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- HCV clinical trial application submitted to Recombinant DNA Advisory Committee (RAC)PR Newswire(Tue, Apr 16)
- Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C InfectionsPR Newswire(Mon, Apr 15)
- Appointment of Mr. Kevin Buchi to Benitec BoardPR Newswire(Wed, Apr 10)
- Benitec Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical TrialPR Newswire(Thu, Mar 21)
- UPDATE 2-Australia iron ore ports re-opening after cycloneat Reuters(Wed, Feb 27)
- UPDATE 1-Cyclone misses Australia iron ore ports, Dampier reopensat Reuters(Wed, Feb 27)
- Powerful Australia cyclone misses iron ore hub Port Hedland, winds easeat Reuters(Wed, Feb 27)
- UPDATE 1-Cyclone intensifies, Australia's iron ore mines braceat Reuters(Tue, Feb 26)
- Powerful cyclone bears down on Australia's top iron ore portat Reuters(Tue, Feb 26)
- UPDATE 1-Australia's top iron ore port braces for direct cyclone hitat Reuters(Tue, Feb 26)
- Australia's top iron ore port braces for direct cyclone hitat Reuters(Mon, Feb 25)
- Benitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) ProgramMarketwired(Thu, Oct 11)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 17.57 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Benitec Biopharma Limited is developing novel treatments for chronic and life-threatening conditions based on gene silencing using a transformational technology, DNA-directed RNA interference (ddRNAi) for human therapeutics.
View More